FDA Approves New Combination Therapy for Metastatic Breast Cancer

The U.S. Food and Drug Administration has authorized a new combination treatment involving palbociclib for adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer. This approval is for maintenance treatment following initial therapy. The decision was based on positive data from the phase 3 PATINA trial, which demonstrated improved progression-free survival.